-
21
-
22
Report of the first seven agents in the I-SPY COVID trial: a phase 2, open label, adaptive platform randomised controlled trialResearch in context
Published 2023-04-01“…Funding for this trial has come from: the COVID R&D Consortium, Allergan, Amgen Inc., Takeda Pharmaceutical Company, Implicit Bioscience, Johnson & Johnson, Pfizer Inc., Roche/Genentech, Apotex Inc., FAST Grant from Emergent Venture George Mason University, The DoD Defense Threat Reduction Agency (DTRA), The Department of Health and Human Services Biomedical Advanced Research and Development Authority (BARDA), and The Grove Foundation. …”
Get full text
Article -
23
Safety and immunogenicity of a variant-adapted SARS-CoV-2 recombinant protein vaccine with AS03 adjuvant as a booster in adults primed with authorized vaccines: a phase 3, parallel...
Published 2023-08-01“…Funding: Sanofi and Biomedical Advanced Research and Development Authority (BARDA).…”
Get full text
Article